Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
binimetinib + erlotinib
- Development stage
- Phase 1
- Lead developer
- Moffitt Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of binimetinib, a potent and selective MEK1/2 inhibitor, and erlotinib, an EGFR tyrosine kinase inhibitor. This combination targets dual inhibition of the MAP kinase pathway, which is activated in both EGFR and KRAS mutant populations. The rationale for combining these agents was to potentially overcome resistance mechanisms and achieve better tumor control in non-small cell lung cancer (NSCLC) patients with EGFR or KRAS mutations.
- Brand names
- Mektovi + Tarceva
02
Targets
Beyond the preview
Go deeper on binimetinib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on binimetinib + erlotinib.